Galderma Marks 30 Years of Restylane Innovation with New Portfolio Approvals and Expansion

Galderma is celebrating the 30th anniversary of Restylane, the first European hyaluronic acid (HA) injectable, which has grown to over 77 million treatments worldwide supported by extensive clinical evidence. Recently, the entire Restylane portfolio achieved EU Medical Device Regulation certification, underscoring its safety and quality standards. Galderma continues to expand the brand with targeted solutions for modern aesthetic needs.

Over three decades, Restylane has evolved from a single product into a versatile portfolio spanning three core technologies: NASHA HD™, NASHA®, and OBT™. Designed to match the skin’s natural HA, the range provides tailored outcomes across the face, décolletage, and hands—ranging from strong structural contouring to soft line-smoothing.

Reinforcing its commitment to safety and quality, the Restylane portfolio recently achieved European Union Medical Device Regulation (EU MDR) certification, meeting one of the world’s most stringent regulatory benchmarks.

Key Innovations and Regulatory Milestones

• Restylane Shaype (EU Approval): Powered by the new NASHA HD™ technology, this is the firmest HA gel among market leaders. It offers a minimally invasive, bone-mimicking alternative to surgical implants for chin enhancement and lower-face structural support.
• Next-Generation Ergonomic Syringe (EU, U.S., Canada): Developed with over 70 aesthetic practitioners, this upgraded syringe features improved ergonomics, easier operation, and 100% recyclable, blister-free packaging that reduces clinic waste by up to 30%. In a survey of over 300 Brazilian healthcare providers, 89% preferred it over standard syringes.
• Restylane Volyme Approval (U.S.): Approved in the U.S. under the name Restylane Contour™, this treatment uses a dual-layer needle/cannula technique to target temple hollowing—a growing concern driven by aging, menopause, and GLP-1 weight-loss medications.

Meeting Evolving Aesthetic Demands

Restylane is increasingly utilized in combination therapies to treat complex aesthetic concerns:

• Menopausal Skin Health: Interim clinical data demonstrates that combining Restylane Skinboosters™ with Sculptra® significantly improves skin hydration, barrier function, and overall quality in menopausal women.
• Weight-Loss Volume Recovery: Combining Restylane Lyft™ or Volyme with Sculptra delivers visible improvements in skin quality and emotional well-being for patients experiencing facial volume loss due to medication-driven weight loss.

Backed by more than 80 clinical trials, 180 publications, and over 77 million treatments globally, Galderma continues to advance the field of aesthetic medicine with science-backed, personalized treatment options.